These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21946305)

  • 21. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 22. Delayed fingolimod-associated asystole.
    Espinosa PS; Berger JR
    Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
    Leypoldt F; Münchau A; Moeller F; Bester M; Gerloff C; Heesen C
    Neurology; 2009 Mar; 72(11):1022-4. PubMed ID: 19289744
    [No Abstract]   [Full Text] [Related]  

  • 24. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fingolimod for the treatment of relapsing multiple sclerosis.
    Singer BA
    Expert Rev Neurother; 2013 Jun; 13(6):589-602. PubMed ID: 23738997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary varicella zoster infection associated with fingolimod treatment.
    Uccelli A; Ginocchio F; Mancardi GL; Bassetti M
    Neurology; 2011 Mar; 76(11):1023-4. PubMed ID: 21403115
    [No Abstract]   [Full Text] [Related]  

  • 27. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 30. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
    Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Huys AC; Lalive PH; Sekoranja L
    Mult Scler; 2014 Apr; 20(5):636-7. PubMed ID: 23897641
    [No Abstract]   [Full Text] [Related]  

  • 33. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
    Komoly S
    Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
    [No Abstract]   [Full Text] [Related]  

  • 34. Rebound of disease activity during pregnancy after withdrawal of fingolimod.
    Sempere AP; Berenguer-Ruiz L; Feliu-Rey E
    Eur J Neurol; 2013 Aug; 20(8):e109-10. PubMed ID: 23829238
    [No Abstract]   [Full Text] [Related]  

  • 35. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis.
    Schwarz A; Korporal M; Hosch W; Max R; Wildemann B
    Neurology; 2010 Jun; 74(24):2022-4. PubMed ID: 20548047
    [No Abstract]   [Full Text] [Related]  

  • 36. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 37. Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.
    Masera S; Chiavazza C; Mattioda A; Superti G; Beggiato E; Crosasso P; Broganelli P; Pinessi L; Cavalla P
    Mult Scler; 2014 Oct; 20(12):1666-7. PubMed ID: 24603883
    [No Abstract]   [Full Text] [Related]  

  • 38. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [2012: Update on diagnosis and treatment of multiple sclerosis].
    Havla J; Kümpfel T; Hohlfeld R
    Dtsch Med Wochenschr; 2012 Apr; 137(17):894-9. PubMed ID: 22492476
    [No Abstract]   [Full Text] [Related]  

  • 40. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.